Status of antihypertensive medication use at severals healthcare facilities in Vietnam in 2025
Main Article Content
Abstract
This study aimed to assess the current situation of antihypertensive drug use in Vietnam in 2025, describe treatment regimens applied in clinical practice, and analyze the trend of single-pill combination (SPC) therapy. A multicenter cross-sectional study was conducted on 3,197 hypertensive patients receiving outpatient treatment at seven healthcare facilities across different regions. Results showed that 54.5% of patients were treated with monotherapy, while 45.5% received combination therapy with two or more agents, including 17.9% using SPCs and 15.9% using free combinations. Triple therapy accounted for 9.8% and quadruple or more for 1.7%. The proportions of patients achieving target blood pressure < 140/90mmHg and < 130/80mmHg were 73.6% and 26.5%, respectively. The use of SPCs was more common in provincial and central hospitals than in primary care settings. These findings indicate a positive shift in hypertension management in Vietnam, with increasing adoption of combination therapy, particularly SPCs, consistent with international recommendations (ISH 2020, ESH 2023, WHO 2025). However, the implementation remains heterogeneous, underscoring the need for standardized prescribing guidance and enhanced training to improve blood pressure control nationwide.
Article Details
Keywords
Hypertension, antihypertensive drugs, Single-pill combination (SPC)
References
2. Global report on hypertension 2025: high stakes: turning evidence into action. Accessed October 13, 2025. https://www.who.int/publications/i/item/9789240115569.
3. Minh HV, Poulter NR, Viet NL, et al. Blood pressure screening results from May Measurement Month 2019 in Vietnam. Eur Heart J Suppl J Eur Soc Cardiol. 2021; 23(Suppl B): B154-B157. doi:10.1093/eurheartj/suab035.
4. Van Minh H, Viet NL, Sinh CT, et al. Blood pressure screening during the May Measurement Month 2017 programme in Vietnam-South-East Asia and Australasia. Eur Heart J Suppl J Eur Soc Cardiol. 2019; 21(Suppl D):D127-D129. doi:10.1093/eurheartj/suz076.
5. Van Minh H, Lan Viet N, Sinh CT, et al. May Measurement Month 2018: an analysis of blood pressure screening results from Vietnam. Eur Heart J Suppl J Eur Soc Cardiol. 2020; 22(Suppl H): H139-H141. doi:10.1093/eurheartj/suaa049.
6. Nguyễn MK, Nguyễn TĐ, Nguyễn NVN. Tình hình thực hiện điều trị, quản lý bệnh tăng huyết áp, và đánh giá kết quả sau can thiệp tại các trạm y tế trên địa bàn thành phố Cần Thơ. Tạp chí Dược học Cần Thơ. 2024; (80): 140-146. doi:10.58490/ctump.2024i80.2860.
7. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874-2071. doi:10.1097/HJH.0000000000003480.
8. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertens Dallas Tex 1979. 2020; 75(6): 1334-1357. doi:10.1161/HYPERTENSIONAHA.120.15026.
9. Hội Tim mạch học Việt Nam. Khuyến cáo về Chẩn đoán và điều trị tăng huyết áp 2022. Hội Tim mạch học Việt Nam; 2022.
10. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation. Accessed October 31, 2025. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356?utm_campaign=sciencenews25-26&utm_source=science-news&utm_medium=phd-link&utm_content=phd-08-14-25.
11. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024; 45(38): 3912-4018. doi:10.1093/eurheartj/ehae178.
12. Chính phủ Việt Nam. Quyết định số 155/QĐ-TTg: Phê duyệt Kế hoạch quốc gia phòng, chống bệnh không lây nhiễm và rối loạn sức khỏe tâm thần giai đoạn 2022 - 2025. January 29, 2022. Accessed September 27, 2025. https://vanban.chinhphu.vn/?pageid=27160&docid=205279.
13. Nguyễn TT, Nguyễn TTH, Mai TH, Phạm TH. Thực trạng kiểm soát huyết áp và một số yếu tố liên quan ở bệnh nhân tăng huyết áp điều trị ngoại trú tại Bệnh viện Đại học Y Hải Phòng. Tạp chí Y học dự phòng. 2019; 29(9): 55-60.
14. Dương NĐ, Lưu ND, Huỳnh TH. Nghiên cứu tình hình và một số yếu tố liên quan ở bệnh nhân tăng huyết áp chưa kiểm soát tại Bệnh viện Đa khoa Kiên Giang năm 2021-2022. Tạp Chí Dược Học Cần Thơ. 2022; 53: 34-40.
15. The Business Standard. Bangladesh makes encouraging progress in controlling hypertension. 2025. Accessed October 15, 2025. https://www.tbsnews.net/bangladesh/bangladesh-makes-encouraging-progress-controlling-hypertension-speakers-1256601.
16. Bruyn E, Nguyen L, Schutte AE, Murphy A, Perel P, Webster R. Implementing Single-Pill Combination Therapy for Hypertension: A Scoping Review of Key Health System Requirements in 30 Low- and Middle-Income Countries. Glob Heart. 17(1): 6. doi:10.5334/gh.1087.